Phase 1 Acute Myeloid Leukemia With FLT3/ITD Mutation Clinical Trials

3 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 1–3 of 3 trials

Recruiting

Phase 1

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaAcute Myeloid Leukemia With FLT3/ITD Mutation+2 more

Uma Borate30 enrolled3 locationsNCT06222580

Recruiting

Phase 1

Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML

Acute Myeloid Leukemia With FLT3/ITD Mutation

H. Lee Moffitt Cancer Center and Research Institute22 enrolled1 locationNCT05024552

Recruiting

Phase 1

A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants

Acute Myeloid Leukemia With FLT3/ITD Mutation

Shijiazhuang Yiling Pharmaceutical Co. Ltd45 enrolled1 locationNCT07162116